NCT00000675View on ClinicalTrials.gov

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

CD4-IgG

Trial Locations (2)

94305

Stanford Univ School of Medicine, Stanford

98105

Univ of Washington, Seattle

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH